FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254788016> ?p ?o ?g. }

• W4254788016 endingPage "S75" @default.
• W4254788016 startingPage "S75" @default.
• W4254788016 abstract "Abstract Background Vedolizumab (VDZ) is an effective treatment for Crohn’s disease (CD); however, inadequate and loss of response is common. Pivotal VDZ trials evaluated alternative dosing intervals, demonstrating numeric but not statistical superiority in efficacy as compared to FDA-approved dosing. The safety and effectiveness of FDA-approved and modified-dosing schedules in a real-world population are unknown. We aimed to evaluate clinical and endoscopic effectiveness & safety of standard and modified maintenance VDZ dosing in a real world cohort. Methods We retrospectively reviewed CD patients (pts) treated with &gt;3 months VDZ, assessing Harvey Bradshaw Index (HBI), Simple Endoscopic Score for Crohn’s disease (SESCD), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), C-reactive protein (CRP), albumin and hematocrit prior to and following standard VDZ dosing, and prior to and following modified VDZ maintenance dosing. We measured duration on therapy and adverse events. Results We identified 226 eligible pts, mean age 41.5 years, 55.3% female, median disease duration 10 years, 88.9% with prior biologic exposure. Mean duration on VDZ was 28.3 months. Standard VDZ dosing: 61.5% of pts with active clinical disease and adequate follow up data achieved clinical response after 3–12 months; 41.0% had clinical remission. 51.9% of pts with active endoscopic disease and adequate follow up data achieved mucosal improvement; 42.3% had endoscopic remission; 26.0% had mucosal healing after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized CRP after 3–12 months. Modified maintenance dosing: 72 non-remitters to standard VDZ dosing received modified VDZ maintenance dosing. 51.5% of pts with active clinical disease prior to starting dose modification and adequate follow up data achieved clinical response after 3–12 months of modified maintenance dosing; 42.4% had clinical remission. 22.2% of pts with SESCD ≥3 prior to starting dose modification achieved mucosal improvement after 3–24 months; 22.2% had mucosal healing. 26.7% of pts with SESCD ≥4 prior to starting modified dosing had endoscopic remission after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized their CRP after 3–12 months. Safety: 82.7% of pts reported ≥1 adverse events, most commonly infection and worsening CD symptoms. Discussion Standard VDZ dosing resulted in clinical and endoscopic improvement in pts with moderate-severe CD, with prior exposure to multiple advanced therapies. For non-remitters to standard dosing, modified VDZ maintenance dosing improved clinical disease activity in ∼50% of pts and improved endoscopic disease activity in ∼20% of pts, suggesting that for pts who did not achieve remission with standard VDZ dosing, modified VDZ dosing may result in clinical and endoscopic improvement." @default.
• W4254788016 created "2022-05-12" @default.
• W4254788016 creator A5052167517 @default.
• W4254788016 creator A5056047149 @default.
• W4254788016 creator A5069562403 @default.
• W4254788016 creator A5079719797 @default.
• W4254788016 date "2020-01-01" @default.
• W4254788016 modified "2023-09-30" @default.
• W4254788016 title "P089 REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE" @default.
• W4254788016 doi "https://doi.org/10.1093/ibd/zaa010.187" @default.
• W4254788016 hasPublicationYear "2020" @default.
• W4254788016 type Work @default.
• W4254788016 citedByCount "0" @default.
• W4254788016 crossrefType "journal-article" @default.
• W4254788016 hasAuthorship W4254788016A5052167517 @default.
• W4254788016 hasAuthorship W4254788016A5056047149 @default.
• W4254788016 hasAuthorship W4254788016A5069562403 @default.
• W4254788016 hasAuthorship W4254788016A5079719797 @default.
• W4254788016 hasBestOaLocation W42547880161 @default.
• W4254788016 hasConcept C112705442 @default.
• W4254788016 hasConcept C126322002 @default.
• W4254788016 hasConcept C141071460 @default.
• W4254788016 hasConcept C197934379 @default.
• W4254788016 hasConcept C2776207728 @default.
• W4254788016 hasConcept C2776694085 @default.
• W4254788016 hasConcept C2777288759 @default.
• W4254788016 hasConcept C2778283404 @default.
• W4254788016 hasConcept C2779134260 @default.
• W4254788016 hasConcept C2779280984 @default.
• W4254788016 hasConcept C2780272996 @default.
• W4254788016 hasConcept C2908647359 @default.
• W4254788016 hasConcept C71924100 @default.
• W4254788016 hasConcept C90924648 @default.
• W4254788016 hasConcept C99454951 @default.
• W4254788016 hasConceptScore W4254788016C112705442 @default.
• W4254788016 hasConceptScore W4254788016C126322002 @default.
• W4254788016 hasConceptScore W4254788016C141071460 @default.
• W4254788016 hasConceptScore W4254788016C197934379 @default.
• W4254788016 hasConceptScore W4254788016C2776207728 @default.
• W4254788016 hasConceptScore W4254788016C2776694085 @default.
• W4254788016 hasConceptScore W4254788016C2777288759 @default.
• W4254788016 hasConceptScore W4254788016C2778283404 @default.
• W4254788016 hasConceptScore W4254788016C2779134260 @default.
• W4254788016 hasConceptScore W4254788016C2779280984 @default.
• W4254788016 hasConceptScore W4254788016C2780272996 @default.
• W4254788016 hasConceptScore W4254788016C2908647359 @default.
• W4254788016 hasConceptScore W4254788016C71924100 @default.
• W4254788016 hasConceptScore W4254788016C90924648 @default.
• W4254788016 hasConceptScore W4254788016C99454951 @default.
• W4254788016 hasIssue "Supplement_1" @default.
• W4254788016 hasLocation W42547880161 @default.
• W4254788016 hasOpenAccess W4254788016 @default.
• W4254788016 hasPrimaryLocation W42547880161 @default.
• W4254788016 hasRelatedWork W2802148294 @default.
• W4254788016 hasRelatedWork W2943962791 @default.
• W4254788016 hasRelatedWork W3006157511 @default.
• W4254788016 hasRelatedWork W3116304527 @default.
• W4254788016 hasRelatedWork W3201963472 @default.
• W4254788016 hasRelatedWork W4229617031 @default.
• W4254788016 hasRelatedWork W4245478085 @default.
• W4254788016 hasRelatedWork W4254788016 @default.
• W4254788016 hasRelatedWork W4360601350 @default.
• W4254788016 hasRelatedWork W3116898088 @default.
• W4254788016 hasVolume "26" @default.
• W4254788016 isParatext "false" @default.
• W4254788016 isRetracted "false" @default.
• W4254788016 workType "article" @default.